Naples

• Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. Th … Recruiting
  2024-516842-21-00 5 2025-01-09 Recurrent ovarian cancer
• Single microdose trial - CXCR4 PET tracer - Pharmacokinetics and pharmacodynamics of [68Ga]Ga-R54, a CXCR4-targeted radiopharmaceutical in p … Recruiting
  2024-513303-14-00 1 2025-01-08 Advanced solid neoplasm (breast, lung, colon, ovary, pancreas) charact
• A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type … Recruiting
  2024-519481-44-00 4 2025-01-08 colorectal metastatic cancer
• A WORLD-WIDE CLINICAL STUDY TO FIND OUT IF INTRAVENOUS RECOMBINANT HUMAN PLASMA GELSOLIN IS SAFE AND IS BENEFICIAL FOR TREATING ACUTE RESPIR … Recruiting
  2023-510109-16-00 4 2025-01-06 Acute Respiratory Distress Syndrome (ARDS) Due to Pneumonia or other I
• PROSPECTIVE EVALUATION OF THE DDR GENES ALTERATION TO PREDICT RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED UROTHELIAL CANCER Recruiting
  2024-516450-21-00 6 2024-12-31 metastatic or locally advanced urothelial cancer
• A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting
  2023-508813-18-00 4 2024-12-18 Refractory Focal Onset Epilepsy
• Randomized phase 2 study of Valproic acid combinEd with rechallenge anti-EGFR based regimen regimens in pretreated patients with RAS/BRAF wi … Recruiting
  2024-514420-16-00 4 2024-12-18 RAS/BRAF wild-type metastatic colorectal cancer
• A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subject … Recruiting
  2024-513860-25-00 9 2024-12-10 Ovarian Neoplasms
• MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, … Recruiting
  2024-516839-27-00 4 2024-12-09 BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
• A single-arm phase II study of cetuximab plus platinum and taxane-based chemotherapy followed by AVElumab and Cetuximab as first-line therap … Recruiting
  2024-512053-24-00 4 2024-12-05 recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSC
• A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys … Recruiting
  2023-508960-31-00 5 2024-12-03 Metastatic HER2-positive breast cancer
• Volrustomig Priming Regimens Exploratory Phase II Platform Study​ Recruiting
  2023-509482-20-00 4 2024-12-03 Solid Tumors
• Prospective phase IIb study to evaluate the efficacy of laparoscopic electrochemotherapy in the treatment of locally advanced pancreatic can … Recruiting
  2024-519067-17-00 4 2024-12-02 Locally Advanced Pancreatic Cancer
• Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI … Recruiting
  2024-517863-22-00 5 2024-12-01 Study population consists in patients with a diagnosis of mCRC who hav
• A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2 trial to evaluate the efficacy and safety of BP1.7881 in … Recruiting
  2023-508949-40-00 4 2024-11-29 Eosinophilic esophagitis
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• Intravenous Fosfomycin in hospitalized patients with complicated urinary tract infections due to Third-generation cephalosporinresistant Ent … Recruiting
  2024-516591-15-00 6 2024-11-12 urinary tract infections
• Efficacy and safety of adjunctive IgM-enriched immunoglobulin therapy with a personalized dose based on serum IgM-titers vs. standard dose i … Recruiting
  2024-518096-57-00 5 2024-11-11 Septic shock
• A study to test if different doses of D3S-001 used on its own or in combination with other anti-cancer medicines is safe and tolerable in pe … Recruiting
  2023-508517-16-00 7 2024-11-10 Advanced Solid Tumors with a KRAS p.G12C Mutation
• Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers Recruiting
  2023-509767-25-00 1 2024-11-07 Advanced PRAME Positive Cancers
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-fibrosis) Recruiting
  2023-509912-27-00 5 2024-11-07 Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
• GSDIa Disease Monitoring Program Recruiting
  2023-510219-20-00 11 2024-11-04 Glycogen storage disease type Ia (GSDIa)
• A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides difficile Infection: The Re … Recruiting
  2022-502972-22-00 5 2024-10-31 Clostridioides difficile infection.

Showing 433–456 of 1,192 trials